Controversy over lung cancer treatment
Post-operative radiotherapy (PORT) is thought to reduce the recurrence of tumours, but the benefits may be cancelled out by the damage it can cause the heart and lungs, particularly in seniors.
The findings of this study fuels the ongoing debate over how much treatment older cancer patients should receive as the medication itself takes a heavy toll on the elderly, and the fact that they may not live long enough to experience the benefits of the treatment.
“The marginal benefit of the additional treatment gets smaller and smaller as patients get older,” Dr David J. Sher, a radiation expert at Rush University Medical Center in the US said in a Reuters Health report. Sher was not involved in the actual study.
The study
Dr Juan Wisnivesky and colleagues of Mount Sinai School of Medicine in the United States, analysed data on more than 1300 patients who’d had surgery for early-stage lung cancer. Such patients usually don’t receive radiation therapy, but in this group the cancer had spread to lymph nodes in the chest.
Although investigators accounted for patient characteristics such as tumour size and type of surgery, that may have influenced the outcome, they could find no benefit linked to radiation therapy after surgery.
There is currently a rigorous clinical trial underway that may shed more light on whether postoperative radiation is a good idea for lung cancer that has invaded the lymph nodes in the chest.
The report suggests that in the interim, patients and doctors should weigh the pros and cons of treatment together.
Sources: Reuters Health
Author
-
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
View all posts
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Controversy over lung cancer treatment
by Health-e News, Health-e News
February 13, 2012